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SUMMARY
Cyclophilins are target molecules for cyclosporin A (CsA), an immunosuppressive antimicrobial drug.We have previously
reported the in vitro anti-Trypanosoma cruzi activity ofH-7-94 and F-7-62 non-immunosuppressive CsA analogues. In this
work, we continue the study of the parasiticidal eﬀect of H-7-94 and F-7-62 CsA analogues in vitro and in vivo and we
analyse 3 new CsA derivatives : MeIle-4-CsA (NIM 811), MeVal-4-CsA (MeVal-4) and D-MeAla-3-EtVal-4-CsA,
(EtVal-4). Themost eﬃcient anti-T. cruzi eﬀect was observed withH-7-94, F-7-62 andMeVal-4 CsA analogues evidenced
as inhibition of epimastigote proliferation, trypomastigote penetration, intracellular amastigote development and in vivo
T. cruzi infection. This trypanocidal activity could be due to inhibition of the peptidyl prolyl cis-trans isomerase activity on
the T. cruzi recombinant cyclophilins tested. Furthermore, CsA and F-7-62 derivative inhibited the eﬄux of rhodamine
123 from T. cruzi epimastigotes, suggesting an interference with a P-glycoprotein activity. Moreover, H-7-94 and F-7-62
CsA analogues were not toxic as shown by cell viability and by aminopyrine-N-demethylase activity on mammalian cells.
Our results show that H-7-94, F-7-62 and MeVal-4 CsA analogues expressed the highest inhibiting eﬀects on T. cruzi,
being promissory parasiticidal drugs worthy of further studies.
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INTRODUCTION
Trypanosoma cruzi is the causative agent of Chagas’
disease, with 200000 new cases occurring each year
in 15 Latin American countries (Moncayo and Ortiz
Yanine, 2006). The chemotherapy of Chagas’ disease
is based on benznidazol, which has undesirable
adverse reactions, so the search for new and
more speciﬁc drugs is encouraged to control the
disease (Urbina and Docampo, 2003; Paulino et al.
2005).
Cyclosporin A (CsA), an immunosuppressant
drug, has an anti-parasitic activity (Bell et al. 1996).
The molecular targets of CsA are the cyclophilins
(CyPs) (Handschumacher et al. 1984), enzymes in-
volved in protein folding through its peptidyl-prolyl
cis-trans isomerase activity (PPIase) (Takahashi et al.
1989). The binary complex CyP-CsA is able to bind
calcineurin, blocking its serine-threonine protein
phosphatase activity, inhibiting the expression
of interleukin-2 in T cells, and triggering immuno-
suppression (Liu et al. 1991). There are CsA
non-immunosuppressive analogues that poorly bind
or do not bind at all to calcineurin (Wenger, 1986).
On the other hand, P-glycoprotein activity is in-
volved in drug resistance, and it has been shown that
CsA and some of its derivatives blocked the trans-
porter activity of P-glycoprotein in certain protozoan
parasites (Silverman et al. 1997; Carrero et al. 2004).
In our laboratory we conﬁrmed that the most ex-
pressed parasite cyclophilin, TcCyP19, exhibited a
CsA-sensitive PPIase activity (Bu´a et al. 2001).
Additionally, we showed the trypanocidal activity of
some non-immunosuppressiveCsA derivatives on all
parasite stages in vitro (Bu´a et al. 2004), described the
cyclophilin gene family in T. cruzi and isolated the
main native CsA-binding proteins (Potenza et al.
2006).
In the present work we studied the parasiticidal
eﬀect of 5 CsA non-immunosuppressive analogues
on in vitro and in vivo T. cruzi infection. We in-
vestigated their possible mechanisms of action such
as the inhibitory eﬀects on parasite cyclophilin
PPIase and P-glycoprotein activities. Moreover,
some aspects of drug toxicity were studied on
mammalian cells with these compounds. Altogether,
our results show that the CsA non-immuno-
suppressive analogues H-7-94, F-7-62 andMeVal-4,
are potent inhibitors of T. cruzi and promissory
parasiticidal drugs.
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MATERIALS AND METHODS
Compounds
Cyclosporin A, MeVal-4-CsA (SDZ 220-384) (Ko
and Wenger, 1997) ; D-MeAla-3-EtVal-4-CsA
(EtVal-4), [Intern. Patent of DEBIOPHARM
S.A. (13.01.2000) WO 00/01715], MeIle-4-CsA
(NIM811) (Traber et al. 1994) were synthesized
and gifted by Dr R. M. Wenger, from Wenger
Chemtech, Riehen, Switzerland. H-7-94, SDZ
208-849, (7-phenyl) (7-desmethyl) MeBmt-1-CsA
(6,7 trans double bond) and F-7-62, SDZ 208-851,
(7-phenyl-6,7-dihydro-(7-desmethyl) MeBmt)-1-
CsA, were originally synthesized by Sandoz, Ltd,
Basel, Switzerland, and gifted by Dr Horst Zahner
from the University of Giessen, Germany. Me is
methyl and Bmt1 is 4 butenyl-4-methyl threonine.
Parasites
T. cruzi CL Brener clone epimastigotes and cell
culture-derived trypomastigotes were cultured as
previously described (Bu´a et al. 2004). T. cruzi
Tulahue´n strain, Tul 2 stock bloodstream trypo-
mastigotes, were obtained from BALB/c mice (Ruiz
et al. 1985).
Eﬀect of CsA and CsA derivatives on epimastigote
proliferation
T. cruzi epimastigotes, at a density of 5r105
parasites/ml, were cultured in 15 ml polystyrene
disposable tubes (Falcon, Oxnard, California), in
1 ml of Brain Heart Infusion medium (BHI) (Difco,
Detroit, Michigan) incubated at 28 xC. Cultures
were then supplemented with diﬀerent drug con-
centrations ranging from 0 to 200 mM. The concen-
tration of the diluent, ethanol, remained below
0.125%. The number of parasites was microscopi-
cally determined in samples obtained at 48, 72, 96
and 144 h of incubation using a Neubauer chamber.
CsA and derivative concentrations producing a 50%
inhibition (IC50) proliferation at 72 h, were estimated
from non-linear regression analysis of parasite
growth rate versus drug concentration, ﬁtting the
equation for a sigmoid plot.
Inhibition of T. cruzi trypomastigote penetration
in vitro
We used 24-well tissue-culture plates (Nunc, Naper-
ville, Illinois) seeded with 104 VERO cells per well,
on 12 mm cover-slips (Fisher, USA). Culture-
derived trypomastigotes were pre-treated with CsA
and CsA analogues, at 25 mM concentration for 1 h in
triplicate for each drug. We chose this dose based on
our previous results, in which this drug concen-
trationwas eﬀective in in vitro experiments (Bu´a et al.
2004). After drug treatment, parasites were washed
with drug-free medium and counted. The infection
of VERO cell monolayers was performed at a 10 : 1
parasite-to-cell ratio for 2 h and then cells were
thoroughly washed. Parasite-infected cells were in-
cubated for 24 h at 37 xC in 5% CO2 with medium
supplemented with 5% fetal bovine serum. Control
parasite-infected cells were performed with 0.3%
drug diluent, ethanol. Covers with cells were re-
moved from culture plates, rinsed with phosphate-
buﬀered saline, air-dried, ﬁxed in methanol and
stained with Giemsa. The infection rate was deter-
mined as the number of cells containing amastigotes
in the cytoplasm. In total, 300 cells (100 cells/cover)
were evaluated for each treatment in randomly
selected ﬁelds. The percentage of penetration in-
hibition was calculated using (average number of
experimental infected cells)x(average number of
control infected cells)r100, divided by (average
number of control infected cells).
Inhibition of T. cruzi amastigote development in vitro
VERO cells were incubated in 24-well tissue-culture
plates on 12 mm cover-slips as described above, and
were infected with 105 culture-derived trypomasti-
gotes for 2 h. After washes, infected cells were
incubated with CsA and analogues, at 25 mM con-
centration, for 48 h. After drug treatment, covers
were processed as indicated above, and cells with
intracellular amastigotes were counted. In total,
300 cells (100 cells/cover) were evaluated for each
treatment in randomly selected ﬁelds.
Treatment of the experimental T. cruzi infection
in mice
CsA and analogues were diluted in olive oil and
administered subcutaneously, 40 mg drug/kg mice/
dose, an amount of drug that has proven to
be eﬀective in a previous study (Rottenberg et al.
1991). Groups of 5 male Balb/c mice, 2 months old,
were pre-treated with CsA and derivatives 12 h in
agreement with previous pharmacokinetics studies
(McCabe et al. 1985) and 2 h before infection with 50
T. cruzi Tulahue´n strain bloodstream trypomasti-
gotes. Drug schedule treatment was performed
with 1 drug dose per day, for 5 days after infection.
Mice survival was checked daily. Parasitaemia was
microscopically assessed from 15 to 40 days post-
infection, analysing fresh blood collected from mice
tails. Ten mice were evaluated for each drug group,
in 2 independent experiments.
Cytotoxic eﬀect measured by MTT viability test
This test was assessed in attached VERO and U937
cell lines. Cells were seeded in 96 wells at a density of
8r103 cells/well. Incubation medium was RPMI
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1640 supplemented with 2 mM glutamine and 0.1%
BSA containing CsA derivatives at diﬀerent con-
centrations: 6.25, 12.5, 25, 50, and 100 mM. Stock
drugs were dissolved in absolute ethanol and this
drug diluent concentration in medium was within
0.03-0.5%. After 18 h, the incubation medium
from VERO cells was aspirated, and 0.5 mg/ml of
MTT (3-{4,5-dimethylthiazol-2-yl}-2.5 diphenyl-
tetrazolium bromide), prepared in RPMI 1640
medium was added. Cells were incubated for 3 h and
then 100 ml of propanol were added to dissolve the
MTT (Fotakis and Timbrell, 2006). Colour was
measured at 540 nm in a microplate reader (Bio-Rad,
model 3550). A 100% viability was considered for
control cells incubated only with medium or treated
with ethanol. Results were expressed as percentage
viability related to log10 dose concentration. MTT
assays were performed in triplicate, in 3 independent
experiments for each cell line.
Eﬀects of CsA analogues on
aminopyrine-N-demethylase activity
The aminopyrine-N-demethylase activity was mea-
sured in cell cultures with a slightly modiﬁed
method (Orrenius, 1968). VERO cells were cultured
in RPMI 1640 (Sigma, St Louis, MO, USA)
medium supplemented with 5% heat-inactivated
fetal calf serum. Cells were seeded at a density of
106 cells per well, in 24-well culture plates (Nunc,
Naperville, Illinois). Cultures were kept in a 5% CO2
incubator at 37 xC for 24 h and growth medium was
changed with RPMI 1640 supplemented with 2 mM
glutamine, 0.1% BSA. CsA and CsA analogues were
added at a concentration of 25 mM. The ﬁnal ethanol
concentration remained below 0.1% including the
non-treated control cultures. Cells were incubated
with CsA and derivatives for 18 h, the incubation
medium was aspirated and replaced by PBS con-
taining 10 mM glucose, 2 mM glutamine and the
substrates needed for the enzymatic reaction: 32 mM
aminopyrine, 4.2 mM MgCl2, 7
.5 mM semicarbazide
and 10 mM dicoumarol (3,3 methylene bis (4-hydroxy
coumarin) (Sigma, St Louis, MO, USA) for inhi-
bition of NADPH-cytochrome C reductase. Cells
were incubated overnight, then 15% ZnSO4 solution
was added to stop the reaction and cold, saturated
Ba(OH)2 was used for protein precipitation.
Supernatants were carefully transferred to another
96-well plate. Formaldehyde diluted in PBS 0; 0.3;
1.56; 3.12; 6.25 to 10 mMwas used as colour standard
related to formaldehyde concentration. Colour was
developed with Nash-reactive in 30% ammonium
acetate (w/v), 0.4% ethyl acetone (v/v) (Nash, 1953)
incubating in a shaker bath at 40 xC (Haake SWB20)
and measured at 415 nm in a microplate reader (Bio-
Rad Model 3550). The enzymatic activity was ex-
pressed in nanomoles of formaldehyde formation
from aminopyrine/mg of protein (Yoshimura et al.
1999). Measurements resulted from 3 independent
assays in triplicate. The Bradford method was used
to estimate protein concentrations (Bradford, 1976).
E. coli expression and puriﬁcation of T. cruzi
cyclophilin recombinant proteins
T. cruzi genes coding for cyclophilins of 19, 21, 25,
28, 34 and 40 kDa, named TcCyP19, TcCyP21,
TcCyP25, TcCyP28, TcCyP34 and TcCyP40 were
cloned in several bacterial expression vectors.
TcCyP19 and TcCyP40 genes were cloned in pQE30
plasmid (Qiagen, GmbH, Germany) and expressed
in E. coli XL1Blue and M15 respectively. TcCyP25
and TcCyP34 genes were cloned in pRSETA
plasmid (Invitrogen, CA, USA) and expressed in
E. coli Origami and Bl21 DE3 strain respectively.
TcCyP28 gene was cloned in pET41.b plasmid
(Novagen, CA, USA) and expressed in E. coli BL21
RIL.TcCyP21 was cloned in pET14, (Novagen, CA,
USA), kindly given byDr ChristopherMehlin, from
SGPP, at the University of Washington, USA, and
expressed in E. coli BL21 PLys strain. All TcCyPs
expressed cyclophilins were puriﬁed by aﬃnity
chromatography on a Ni2-nitriloacetate agarose
column (Qiagen, GmbH, Germany) following the
manufacturer’s protocol. Puriﬁed protein fractions
were pooled, dialysed against 50 mM HEPES (N-2-
hydroxyethylpiperazine Nk-2 ethanesulfonic acid
sodium salt), pH 7.5, checked by SDS-PAGE, and
quantiﬁed according to the Bradford method.
Peptidyl prolyl cis-trans isomerase activity assay
of TcCyP19 expressed protein
Progress of chymotryptic cleavage of the substrate
N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide (Sigma,
St Louis, MO, USA) in the enzymatic activity assays
was monitored by measuring A390 on a Beckman
Coulter DU640 spectrophotometer (Beckman In-
struments, CA, USA), essentially as described
(Fischer et al. 1984;Kofron et al. 1991). The reaction
was initiated by adding 75 mM substrate to 0.5 ml of
assay mixture containing 35 mM HEPES, 100 mM
NaCl buﬀer, pH 7.9. Diﬀerent amounts of puriﬁed
expressed TcCyP19, TcCyP21, TcCyP25, TcCyP28,
TcCyP34 and TcCyP40 recombinant proteins were
added (at concentrations ranging from 0 to 200 nM)
together with 100 mg a-chymotrypsin (Sigma,
St Louis, MO, USA) to cleave the chromogenic
p-nitroanilide. Reactions were performed at 5 xC.No
recombinant protein was added in control samples.
Inhibition of recombinant proteins PPIase activity
The eﬀect of CsA and derivatives : H-7-94, F-7-62
and MeVal-4 were tested as inhibitors of the enzy-
matic activity of the T. cruzi cyclophilins: TcCyP19,
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TcCyP21, TcCyP25, TcCyP28, TcCyP34 and
TcCyP40. Puriﬁed recombinant proteins were pre-
incubated with diﬀerent drug concentrations ranging
from 0 to 1 mM, for 10 min at 5 xC. Then, the reaction
was initiated as described above.
Rhodamine eﬄux assays
Several sets of 1r108 T. cruzi CL Brener clone
epimastigotes were resuspended in phosphate-
buﬀered saline, pH 7.4 (PBS) containing 1 mg/ml
rhodamine and incubated for 30 min at 28 xC. For
the dead parasite control, epimastigotes were heat-
killed at 65 xC for 30 min prior to dye incubation.
Parasites were washed twice with ice-cold PBS in the
presence or absence of drug inhibitors such as CsA,
F-7-62 or Verapamil (Sigma, St Louis, MO, USA).
Then, epimastigotes were resuspended in 10 ml of
BHI plus drugs, and control parasites in BHI plus
ethanol, the drug vehicle, and incubated at 28 xC.
Parasites were pelleted at 9000 g for 10 min at 15, 30,
60 and 240 min. Supernatants were collected and
Rhodamine 123 eﬄux ﬂuorescence was measured
at an excitation and emission of 485 and 530 nm
wavelength, respectively, using a Jasco-770 spectro-
ﬂuorometer (Jasco, Japan), a facility kindly provided
by Dr Carlos Stella, from the Department of
Biological Chemistry, Faculty of Medicine, Univer-
sity of Buenos Aires. The concentration of released
rhodamine 123 was calculated by interpolation on a
dye standard curve using serum-free BHI as diluent.
Experiments were performed in duplicate samples,
in 3 independent experiments.
Statistical analysis
Assays were performed in duplicate or triplicate, as
previously indicated, in 2–4 independent experi-
ments. The dose response curves were obtained
by linear regression analysis using the computer
program Origin Version 6. Statistical analysis of the
in vitro parasite experiments was performed using
Student’s t-test, for paired values, using Microsoft
Excel, 97. The values presented are the means¡S.D.
of 2 or more independent experiments. Values of
P<0.05 were considered statistically signiﬁcant.
RESULTS
Eﬀect of CsA derivatives on T. cruzi in vitro
Eﬀect of CsA and CsA derivatives on epimastigote
growth. Inhibition of epimastigote proliferation by
CsA and 3 new CsA analogues was studied. The re-
duction of epimastigote growth rate was established
at 72 h after treatment in comparison with parasites
that were cultured in drug-free medium. The IC50
obtained for EtVal-4, MeIle-4 and MeVal-4 were
4.52, 0.64 and 2.32 mM respectively, while CsA
showed an IC50 of 5
.39 mM (Table 1). Results ob-
tained with CsA, H-7-94 and F-7-62 have previously
been published elsewhere (Bu´a et al. 2004) and were
included in this table for comparison.
Inhibition of trypomastigote penetration in
VERO cells
The anti-parasitic eﬀects of CsA analoguesMeVal-4,
MeIle-4 and EtVal-4 were analysed in comparison
with H-7-94 and F-7-62. The best inhibition on
trypomastigote penetration in VERO cells was ob-
tained when parasites were pre-incubated with 25 mM
of theH-7-94, F-7-62 andMeVal-4 CsA analogues, a
dose which has previously been found eﬀective on in
vitro infection (Bu´a et al. 2004). In this report, other
experimental conditions were tested in which vi-
ability of treated trypomastigotes was followed by
microscopical observation and viable parasite count-
ing. Control experiments were performed with
0.25% ethanol, as vehicle. F-7-62 inhibited 84% of
trypomastigote penetration as compared to the drug-
free control. H-7-94 and MeVal-4 exhibited an in-
hibition of 75 and 70% respectively (Fig. 1A). CsA,
EtVal-4 and MeIle-4 inhibited 52 to 58% of parasite
penetration. The eﬀects of all CsA derivatives at
25 mM concentration were signiﬁcantly diﬀerent
(P<0.05) with respect to the control experiment.
Inhibition of the development of intracellular
amastigotes
Infected cell cultures were incubated for 48 h with
CsA analogues at a drug concentration of 25 mM. All
drugs showed a marked inhibitory eﬀect on intra-
cellular amastigote development, showing an inhi-
bition of 88.6% for F-7-62, 87% for MeVal-4, 83.6%
for H-7-94 and 76% for EtVal-4, as compared to the
control drug-free medium-treated cells. CsA in-
hibited 37.5% of the intracellular amastigote devel-
opment. Fig. 1B shows the percentage of VERO cells
Table 1. Parasites grown in the presence of CsA
and CsA derivatives
(Drug non-treated parasites with ethanol, as negative
control. IC50 values for inhibition of epimastigote pro-
liferation were estimated at 72 h after treatment. Four in-
dependent experiments, in duplicate, were done for each
drug concentration.)
Treatment
Epimastigote growth
inhibition
(IC50 in mM)
CsA 5.39
H-7-94 0.82
F-7-62 3.41
EtVal-4 4.52
MeIle-4 0.64
MeVal-4 2.32
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containing T. cruzi amastigotes and the eﬀect of CsA
derivatives H-7-94, F-7-62, MeVal-4, MeIle-4 and
EtVal-4 treatment, which resulted in a signiﬁcant
decrease in infected cells.
Treatment of experimental T. cruzi infection in mice
Balb/c mice infected with T. cruzi bloodstream try-
pomastigotes, were treated with CsA analogues prior
to and during the ﬁrst 5 days post-infection (p.i.).
Parasitaemia and mice survival were recorded until
40 days p.i. Survival was 100% in animals treated
with H-7-94, F-7-62 and MeVal-4. The peak para-
sitaemia, at 23 days p.i., for these drugs was signiﬁ-
cantly diﬀerent (P<0.01) from the parasitaemia of
control animals, inoculated with olive oil, (4.81¡
1.2r106/ml) and CsA-treated and infected mice
(8.7¡1.9r106/ml). F-7-62, H-7-94 and Me Val-4
reduced the circulating parasites to 1.71¡0.75r106/
ml, 1.85¡0.74r106/ml and 2.85¡0.61r106/ml, re-
spectively (Fig. 2A).
Mice treated with the MeIle-4 and EtVal-4 CsA
analogues did not exhibit signiﬁcant diﬀerences in
parasitaemia with respect to control mice (Fig. 2B)
and survival was 90%. It is worth noting that 50% of
mice survived with CsA treatment and 60% of the
non-treated control group (Fig. 2C).
Toxicity evaluation of CsA derivatives on
mammalian cells
We have analysed the toxicity of the CsA analogues
H-7-94, F-7-62 and 3 new ones: MeVal-4, MeIle-4
and EtVal-4 on mammalian cell viability by the
MTT test. As previously shown in our laboratory,
H-7-94 and F-7-62 CsA derivatives are not toxic for
VERO cells as shown by the Trypan blue viability
method (Bu´a et al. 2004). In this report, VERO cells,
derived from green monkey kidneys and U937 cells,
derived from a human myeloid lymphoma, were
used. MeIle-4 and CsA decreased cell viability as
measured by the MTT method in both cell lines,
U937 cells being more sensitive than VERO cells.
The CsA ED50 (eﬀective dose for 50% cell vi-
ability) was 21.61 mM¡4.2 in VERO cells but
4.08 mM¡5.53 in U937 cells. The MeIle-4 CsA
analogue showed an ED50 equal to 42
.5 mM¡6.85
in VERO cells but 12.5 mM¡5.85 in U937 cells
(Fig. 3B). EtVal-4, H-7-94 and F-7-62 derivatives,
exhibited less toxic eﬀects, not aﬀecting VERO cells,
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Fig. 1. Eﬀects of CsA analogues on Trypanosoma cruzi in vitro. Drugs were used at a 25 mM concentration.
(A) Inhibition of trypomastigote penetration by CsA analogues. Parasites were pre-incubated for 1 h with drugs and
infected VERO cells. F-7-62 was the best drug, inhibiting 84% of parasite penetration. All CsA derivatives exhibited
inhibition eﬀects signiﬁcantly diﬀerent (P<0.05) as compared to the drug-free medium control. (B) Eﬀects of CsA
analogues on the development of intracellular amastigotes. CsA analogues were present in the cell culture medium
for 48 h. All CsA analogues showed inhibitory eﬀects on amastigote development. F-7-62, the most eﬀective drug,
inhibited 88.6% as compared to drug-free medium-infected cells.
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U937 cells being once again more sensitive at higher
doses than the ED50. MeVal-4 CsA analogue, was not
toxic for U937 cells. On VERO cells, 90% of cells
were viable at a 25 mM MeVal-4 concentration,
although at 50 mM, 80% of VERO cells died; how-
ever, this dose exceeds the range in which trypano-
cidal eﬀects are evident (Fig. 3A).
Since CsA is metabolized by the cytochrome P450
system, which catalyses the hydroxylation and de-
methylation of the drug, another toxicity parameter
was also tested in cell cultures treated with CsA and
derivatives: the aminopyrine demethylase enzymatic
activity (Bertault-Peres et al. 1987; Watkins, 1990;
Pichard et al. 1991; Gan et al. 1996). A signiﬁcant
increase in enzymatic activity was found in cells
treated with CsA and most of its analogues at 25 mM
concentration, compared to cells treated with
ethanol. As CsA is considered a positive control, it is
worth noting that H-7-94 and F-7-62-treated cells
showed signiﬁcantly less augmentation of enzymatic
activity than CsA-treated cells. EtVal-4 was the only
15 20 25 30 35 40
0
2
4
6
8
10
12
Pa
ra
si
te
m
ia
 (x
E6
)
Days post-infection
Cyclosporin A
Control
F-7-62
H-7-94
Me Val-4
15 20 25 30 35 40
0
2
4
6
8
10
12 B
C
A
Pa
ra
si
te
m
ia
 (x
E6
)
Days post-infection
Control
Cyclosporin A
MeIle-4
EtVal-4
15 20 25 30 35 40
4
6
8
10
 H-7-94
 F-7-62
 MeVal-4
 EtVal-4
 MeIle-4
 Control
 CsACu
m
ul
at
iv
e 
m
ic
e 
su
rv
iv
al
Days post-infection
Fig. 2. Eﬀects of CsA analogues on Trypanosoma cruzi
in vivo. Balb/c mice were treated with drugs as described
and infected with bloodstream trypomastigotes. Peaks of
parasitaemia were recorded at 23 days p.i. (A) The most
eﬀective drugs, F-7-62, H-7-94 and MeVal-4, showed
signiﬁcantly diﬀerent parasitaemias than control animals.
(B) Less eﬀective drugs, MeIle-4 and EtVal-4, showed
no signiﬁcant diﬀerences from control groups. Fig. 2C.
Mice survival was 100% with F-7-62, H-7-94 and
MeVal-4 treatment.
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Fig. 3. Toxicity of CsA analogues in mammalian cells.
The MTT test was assayed in mammalian cells. Drugs
were tested at diﬀerent concentrations as described. A
100% viability was considered for ethanol-treated cells
as a control. Experiments were performed in triplicate.
(A) Cyclosporin A and analogues, eﬀect on VERO
cell viability by the MMT test. (B) Cyclosporin A
and analogues, eﬀect on U937 cell viability by the MMT
test.
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CsA derivative tested in this assay that showed
similar levels of aminopyrine N-demethylase enzy-
matic activity, as ethanol-treated cells (Table 2).
Susceptibility of T. cruzi cyclophilin enzymatic
activity to CsA analogues
The isomerization of the Ala-Pro bond coupled with
chymotryptic cleavage of the trans-peptide was
measured as the increase of absorbance at 390 nm.
The puriﬁed His-tagged recombinant cyclophilins :
TcCyP19, TcCyP21, TcCyP25, TcCyP28, TcCyP34
andTcCyP40 clearly accelerated the rate of cis – trans
isomerizationof thepeptide substratecomparedto the
control without the recombinant proteins, showing
that they are active PPIases that could be inhibited
by the 3 most eﬃcient trypanocidal CsA derivatives,
H-7-94, F-7-62 andMeVal-4.
The IC50 was determined for each compound and
is displayed in Table 3 for each T. cruzi cyclophilin.
The inhibition of the PPIase assay of these T. cruzi
enzymes was performed using concentrations of
0.020 to 4 mM of recombinant protein pre-incubated
with diﬀerent concentrations, from 0 to 1 mM, of
CsA, H-7-94, F-7-62 and MeVal-4. TcCyP25 and
TcCyP40 showed a much higher IC50 for these drugs
(over 200 nM concentration) being coincident with
the histidine substitution, in these two T. cruzi
cyclophilins, for the critical tryptophan residue for
CsA binding (Potenza et al. 2006).
Eﬀect of CsA on rhodamine eﬄux of T. cruzi
epimastigotes
To study the inhibition capacity of CsA on the
parasite P-glycoprotein, the hydrophobic ﬂuorescent
dye rhodamine 123 eﬄux assay was used (Eﬀerth
et al. 1989). Untreated T. cruzi epimastigotes
accumulated rhodamine 123, and an eﬄux into the
culture medium could be observed. This dye
eﬄux was clearly inhibited by CsA and F-7-62
CsA derivative, as well as by Verapamil, a classic
P-glycoprotein inhibitor.Heat-killed parasites show-
ed no rhodamine eﬄux activity (Fig. 4A). After 4 h of
dye eﬄux, the percentages of inhibition were similar
for CsA and Verapamil, at a concentration of 1 mg/ml
for both drugs, being 63% and 64% respectively.
A better inhibition, of 72%, was observed for F-7-62
at 1 mg/ml, and 73% for CsA at 10 mg/ml. These
results showed a 10-fold more eﬃcient inhibition
performance of this CsA analogue regarding CsA,
as indicated in Fig. 4B.
DISCUSSION
In this work it is shown that CsA and the non-
immunosuppressive analogues H-7-94, F-7-62 and
MeVal-4, had a clear anti-T. cruzi eﬀect in vitro and
on T. cruzi experimental infections in vivo. The
trypanocidal drugs with the best performance
inhibited the enzymatic activities of 6 T. cruzi
recombinant cyclophilin proteins, including those
best expressed in the parasite. It was also established
that CsA and 1 of the CsA derivatives inhibited a
P-glycoprotein activity on T. cruzi. Moreover, these
derivatives exhibited less toxic eﬀects on cell vi-
ability and on activation of cell aminopyrine-N-
demethylase than CsA.
H-7-94 and F-7-62, have less immunosuppressive
activity than CsA (Zahner and Schultheiss, 1987)
and MeVal-4 is non-immunosuppressive (Zenke
et al. 1993), not binding calcineurin. These analogues
had a trypanocidal activity at the micromolar level.
H-7-94, F-7-62 and MeVal-4-CsA were 1.25 to 1.5-
fold and 2.0 to 2.3-fold more eﬀective than CsA in
inhibiting trypomastigote penetration and amasti-
gote development, respectively.
The studies of these trypanocidal drugs were
further evaluated in experimentalT. cruzi infections.
H-7-94, F-7-62 and MeVal-4 CsA analogues
protected T. cruzi-infected mice from high para-
sitaemias such as those observed in control animals.
CsA-treated infected animals showed even higher
parasitaemias than non-treated animals, as pre-
viously observed (McCabe et al. 1985). These drug
treatments exhibited a remarkable fact regarding
mice survival. None of the CsA analogue-treated
mice died after 40 days post-infection, while a
mortality of 40%was observed in control non-treated
animals, and 50% in CsA-immunosuppressed mice.
The CsA analogues H-7-94 and F-7-62 were also
used in other pathologies such as infections by
Litomosoides carinii (Zahner et al. 1987) and in
malaria (Grau et al. 1987). The NIM811 (MeIle-4)
CsA analogue, used in this work, has proven to
be active against HIV virus (Billich et al. 1995),
Hepatitis C (Ma et al. 2006) and was also cyto-
protective in neuronal cells (Waldmeier et al.
Table 2. Aminopyrine N-demethylase activity in
Vero cells treatedwith 25 mMCsA andCsA analogues
(Control VERO cells treated with ethanol showed an
increased enzymatic activity (*P<0.001) compared to the
cells cultured only with medium. In cells treated with the
H-7-94, F-7-64 and Etval-4 CsA analogues the enzymatic
activity signiﬁcantly decreased (# P<0.05) compared to
cells treated with CsA.)
Treatment
Formaldehyde
(nM/mg protein) S.D. n
Medium 173.17 19.5 4
Control 332.30 9.30 4*
EtVal-4 386.00 17.91 4#
H-7-94 546.73 60.13 4#
F-7-62 684.00 22.91 3#
MeVal-4 1605.43 63.46 3
Melle-4 1747.94 41.15 3
CsA 2326.19 325.6 4
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2002; Hansson et al. 2004). Although this CsA
analogue was used as an anti-malaria drug onPlasmo-
dium vivax, with a similar parasiticidal activity as
CsA (Kocken et al. 1996), NIM811 (MeIle-4) has
not been very eﬀective against T. cruzi.
Toxicity was studied on cell viability measured
by the MTT test, an accepted reliable method used
to measure toxic concentrations of chemicals in
human blood (Jover et al. 1992). The aminopyrine
demethylase enzymatic activity was also used as a
toxicity parameter in cell cultures. The cells treated
with H-7-94, F-7-62, and EtVal-4 did not exhibit
toxic eﬀects while MeIle-4 and CsA were toxic. It
is remarkable that Me-Val-4 exhibited a diﬀerent
behaviour regarding the cell line tested, it was
innocuous on U937 human cells (Song et al. 2003)
although VERO cells were sensitive to the drug.
As previously stated, CsA has been shown to be
metabolized by the cytochrome P450 system, which
catalyses the hydroxylation and demethylation of the
drug. The activity of this enzyme was also described
in kidneys, and localized in proximal tubular cells
(Yoshimura et al. 1999) ; it is induced by many
xenobiotics in vivo and in vitro (Guillouzo, 1998).
H-7-94 and F-7-62 CsA analogues proved to induce
an aminopyrine-N-demethylase activity signiﬁcantly
lower than CsA. To evaluate the enzyme activity, a
concentration of 25 mM, that highly exceeded the IC50
previously reported for the most eﬀective CsA ana-
logues (0.82–7.19 mM), was used on epimastigotes,
trypomastigotes and inhibition of parasite pen-
etration (Bu´a et al. 2004).
The in vitro and in vivo trypanocidal activity of
some CsA derivatives shown in this study could be
associated with inhibition of their target molecules in
the parasite, the cyclophilins. A previous study
demonstrated that theT. cruzi cyclophilin of 19 kDa,
TcCyP19, had a CsA-susceptible PPIase activity
(Bu´a et al. 2001) and it was also shown that all CsA
analogues tested had an inhibitory eﬀect on the
TcCyP19 enzymatic activity, inhibited best by
H-7-94 and F-7-62 CsA derivatives (Bu´a et al. 2004).
H-7-94, F-7-62 and MeVal-4 CsA derivatives were
able to inhibit the peptidyl prolyl cis-trans isomerase
activity of TcCyP19, the most expressed paralogue
in the parasite (Potenza et al. 2006), and also the
enzymatic activity ofTcCyP21,TcCyP25,TcCyP28,
TcCyP34 and TcCyP40 recombinant proteins.
Although the inhibition of PPIase activity by these
drugs was conﬁrmed for every T. cruzi recombinant
cyclophilin tested, in the case of TcCyP25 and
TcCyP40 a much higher concentration of CsA ana-
logues, between 200 and 400 nM, was necessary to
inhibit the enzymatic activity. A histidine substi-
tution for tryptophan was observed in these two cy-
clophilins (Potenza et al. 2006), and this residue was
shown to be essential for CsA binding. This fact is in
accordance with several other reports in which large
cyclophilins bind CsA with less aﬃnity than smaller
cyclophilins (Galat, 1999). Since the IC50 of CsA,
H-7-94, F-7-62 and MeVal-4-CsA on cyclophilins
TcCyP25 and TcCyP40, was over 200 nanomolar,
these molecules would not be the primary targets
for the CsA and CsA analogues tested in this work,
and very unlikely responsible for the trypanocidal
activity observed on these drugs in vitro and in vivo.
The gene coding for the human archetypal cyclo-
philin CyPA or hCyP18, was cloned and expressed in
the pQE vector yielding an active and CsA-sensitive
PPIase activity. An IC50 of 23 nM was obtained for
CsA on this human enzyme, in good agreement with
a previous report (Picken et al. 2002). The inhibition
of hCyP18 enzymatic activity by H-7-94 and F-7-62
CsA analogues appeared to be less eﬃcient than CsA,
suggesting a weaker binding with the human cyclo-
philin. The IC50 for both drugs was 3-fold higher
(65–70 nM) than the CsA IC50. This fact could be
attributed to the phenyl group present in these two
CsA analogues, on MeBmt in position 1 of CsA that
probably is less tolerated by hCyP18.
Table 3. Inhibition of PPIase activity of several recombinant
Trypanosoma cruzi cyclophilins
(CsA analogues were pre-incubated in diﬀerent concentrations from 0 to 1 mMwith
the recombinant proteins, and PPIase activity was performed as described. IC50
was calculated from computer programs as Excel and Origin version 6.)
Recombinant Drugs (IC50)
T. cruzi
cyclophilins
CsA
(nM)
H-7-94
(nM)
F-7-62
(nM)
MeVal–4
(nM)
TcCyP19 14.42 12.54 13.3 15.25
TcCyP21 28.74 23.64 25.15 30.04
TcCyP28 31.7 17.2 17.8 28.98
TcCyP34 13.05 9.16 10.06 13.52
TcCyP25 >200 >200 >200 >200
TcCyP40 >200 >200 >200 >200
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A recent study of molecular modelling and dy-
namic simulation has shown that the phenyl group
in the MeBmt1 residue present in the H-7-94 and
F-7-62 CsA analogues, provided a higher potential
energy, which means a higher stability of these com-
plexes compared with the TcCyP19-CsA complex
(Carraro et al. 2007). Based on this, the inhibitory
eﬀects of the H-7-94 and F-7-62 CsA analogues
against T. cruzi parasites could be attributed to their
chemical structure.
All T. cruzi cyclophilins tested so far, despite the
level of protein expression in the parasite, could be
potential targets of these parasiticidal drugs, such as
TcCyP21,TcCyP28,TcCyP35, andwith less aﬃnity,
TcCyP25 and TcCyP40. But, as previously shown,
TcCyP19 is the CsA-binding protein most widely
Control CsA 1 µg/ml CsA 10 µg/ml F-7-62 1 µg/ml Ver 1 µg/ml
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Fig. 4. Eﬀect of CsA and F-7-62 analogues on the rhodamine 123 eﬄux in Trypanosoma cruzi epimastigotes. (A) CsA
at 1 and 10 mg/ml or F-7-62 at 1 mg/ml were tested as inhibitors of rhodamine 123 eﬄux. Verapamil and heat-killed
parasites were used as negative controls. Rhodamine ﬂuorescence was determined in the supernatant at an excitation of
485 nm and emission of 530 nm at diﬀerent times. Y-axis standard deviation is shown only for live parasites and
Verapamil-treated parasites in order to avoid multiple overlapping lines. (B) Inhibition of rhodamine eﬄux was
measured after a 4-h parasite incubation. For Verapamil (Ver), CsA and the F-7-62 CsA analogue-treated parasites,
rhodamine eﬄux signiﬁcantly diminished (P<0.05) compared to untreated parasite controls. Three independent
experiments, in duplicate, were done for each drug concentration.
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expressed in the parasite (Potenza et al. 2006) thus,
the CsA trypanocidal eﬀects are probably mainly
exerted by the TcCyP19-CsA analogue complex.
In addition, another probable target molecule for
CsA and the most active derivative, F-7-62, was
described by us onT. cruzi. Both drugs inhibited the
rhodamine eﬄux suggesting an inhibition of a para-
site P-glycoprotein. Two T. cruzi genes were de-
scribed for P-glycoproteins so far, tcpgp2 and tcpgp1
(Dallagiovanna et al. 1996; Torres et al. 1999). These
molecules belong to the ATP-binding cassette
(ABC) superfamily of transporters and play an im-
portant role in multi-drug resistance in eukaryotic
cells and in protozoan parasites (Silverman et al.
1997; Carrero et al. 2004). It is worth noting that
F-7-62 inhibition of rhodamine eﬄux at a concen-
tration of 1 mg/ml exhibited a similar level of inhi-
bition as CsA at 10 mg/ml. This feature has been
observed before, when the F-7-62 and H-7-94 CsA
analogues were tested on inhibition of T. cruzi
epimastigote proliferation (Bu´a et al. 2004). In this
experiment, higher concentrations of the F-7-62
derivative resulted in a massive dye eﬄux due to a
lytic eﬀect on the parasite.
A more detailed analysis of the T. cruzi target
molecules, the cyclophilins and P-glycoproteins
complexed with CsA analogues will be useful in
understanding the mode of action of these drugs.
The results obtained in this work with the more ef-
ﬁcient trypanocidal compounds, H-7-94 and F-7-62,
warrant a pre-clinical study to improve the chemo-
therapy against Chagas’ disease.
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